Targeting TIGIT for cancer immunotherapy: recent advances and future directions

被引：0
作者：
Peng Zhang
Xinyuan Liu
Zhuoyu Gu
Zhongxing Jiang
Song Zhao
Yongping Song
Jifeng Yu
机构：
[1] the First Affiliated Hospital of Zhengzhou University,Department of Thoracic Surgery
[2] Henan Medical Key Laboratory of Thoracic Oncology,Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences
[3] Henan University,Department of Hematology
[4] the First Affiliated Hospital of Zhengzhou University,Henan International Joint Laboratory of Nuclear Protein Gene Regulation
[5] Henan University College of Medicine,undefined
来源：
Biomarker Research | / 12卷
关键词：
TIGIT; Target immunotherapy; Immune checkpoint pathway; cancer immunotherapy; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT has been associated with NK cell exhaustion in vivo and in individuals with various cancers. It not only modulates NK cell survival but also mediates T cell exhaustion. As the primary ligand of TIGIT in humans, CD155 may be the main target for immunotherapy due to its interaction with TIGIT. It has been found that the anti-programmed cell death protein 1 (PD-1) treatment response in cancer immunotherapy is correlated with CD155 but not TIGIT. Anti-TIGIT alone and in combination with anti-PD-1 agents have been tested for cancer immunotherapy. Although two clinical studies on advanced lung cancer had positive results, the TIGIT-targeted antibody, tiragolumab, recently failed in two new trials. In this review, we highlight the current developments on TIGIT for cancer immunotherapy and discuss the characteristics and functions of TIGIT.
引用
收藏
相关论文
共 1976 条
[1]  
Wang Y(2022)Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts J Hematol Oncol. 15 111-875
[2]  
Zhang H(2022)Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol. 15 6-1855
[3]  
Liu C(2022)Exploring immunotherapy in colorectal cancer J Hematol Oncol. 15 95-1867
[4]  
Wang Z(2022)Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors J Hematol Oncol. 15 87-57
[5]  
Wu W(2019)Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial J Thorac Oncol. 14 867-703
[6]  
Zhang N(2016)Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy N Engl J Med. 375 1845-915
[7]  
Zhang L(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med. 375 1856-180
[8]  
Hu J(2022)Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia Exp Hematol Oncol. 11 11-892
[9]  
Luo P(2022)Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation J Hematol Oncol. 15 24-792
[10]  
Zhang J(2018)Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature J Immunother Cancer. 6 126-697
12345678910